RetaMaps

Complete Clinics

Complete Clinics · 1800 Nations Drive · Gurnee, IL 60031

4.5· 14 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Complete Clinics is a weight-loss, hormone and aesthetics practice in Gurnee, Illinois. On Google it holds a 4.5-star rating across 14 reviews dating back to 2017, with 1 in the past year. Reviewers most often mention the staff, with 6 citing results and a few noting the providers' knowledge and feeling cared for. We could not read a website for this practice, so ask the office which weight-management options it currently offers.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.5
Google rating · 14 reviews
1
reviews in the past year (avg ★ 2.0)
5
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-01-09. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.5 across 14 Google reviews. Of the 14 reviews we analyzed, 12 (86%) are positive (4–5★) and 2 (14%) are negative (1–2★).

What patients like

  • Friendly, helpful staff7 reviews
  • Weight-loss results6 reviews
  • Knowledgeable, professional providers3 reviews
  • Feeling listened to3 reviews

Common complaints

Very few complaints — only 2 negative reviews, with no recurring theme.

5★
12
4★
0
3★
0
2★
1
1★
1

Most recent Google reviews

Georgina V.★★★★★2026-01-09

El horario no es confiable llegó hoy 01/09/26 a la clínica a la 1p.m y no estaba abierto llame antes de venir y tampoco contestaron la llamada

Rose W.★★★★★2025-07-01

I love the gurnee branch.very professional and caring

Priscella W.★★★★★2024-01-04

Great experience. I love 💕 my results and the team of staff is amazing.

Dyana L.★★★★★2023-07-25

Love the place love the atmosphere good to get injections as well with weight loss

Kayla C.★★★★★2023-05-19

Complete Clinics is amazing! The staff is so encouraging and confident in helping you. I have lost 30 lbs in 2 months with the help of them and I continue to push forward. I love going there for help with my weight loss and I will continue to go there!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Gurnee

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs